Kornimate/medical-research-clean huggingface dataset:
quality of life study about the role of turbinectomy in rhinoseptoplasty

Conditions: Deviated Nasal Septum; Nasal Septal Defect; Nasal Septum, Irregular

Summary: research question: performing partial turbinectomy associated with rhinoseptoplasty is responsible for an increase in quality of life related to nasal obstruction when compared to no intervention in rhinoseptoplasty inferior turbinate? * population: patients eligible for functional rhinoseptoplasty and / or aesthetic * intervention: surgery, turbinectomy of inferior turbinates * comparison: the absence of intervention in inferior turbinates * primary endpoint: quality of life related to nasal obstruction


Eligibility criteria:
inclusion criteria: * eligible patients to rhinoseptoplasty * patients who agreed to participate exclusion criteria: * presence of symptoms of nasal obstruction in the absence of septal deviation, poor support of the nasal tip or clamping of the nasal valve; * presence of hypertrophic and obstructive inferior turbinates; * presence of sinonasal tumors; * patients undergoing treatment of other concomitant rhinoplasty entities such as inflammatory sinus pathology, adenoid hypertrophy, septal perforation, otoplasty and blepharoplasty.

Keywords: rhinoseptoplasty
weight loss in pre-diabetic, obese women

Conditions: Obesity

Summary: this is a six (6) month, single center, randomized, double-blind, parallel, controlled-feeding weight-loss study comparing two dietary groups (triglyceride and olestra) in pre-diabetic obese women.


Eligibility criteria:
inclusion criteria: * premenopausal * bmi 30-45 kg/meter squared * waist circumference greater than 88 cm * blood glucose level 5.8-6.9 mmol/l exclusion criteria: * pre-diabetic * pregnant * nursing * food preferences not compatible with the study diet * allergies or food sensitivities with any of the study diet

Keywords: pre-diabetic obese
the effect of n-acetylcysteine on oxidative stress status and iron overload in thalassemia major

Conditions: Thalassemia Major

Summary: the effect of n-acetylcysteine as antioxidant and its effect on pretransfusion hemoglobin and iron overload in patients with thalassemia were compared to patients who didn't receive n-acetylcysteine after 3 months of study duration

n-acetylcysteine( nac) is a widely used mucolytic drug and several studies had reported its efficacy as anti oxidant. patients with thalassemia major are at great risk for oxidative stress due to excess of b-globin chains and iron overload. in this study the investigators compared the effect of nac on oxidative status , pretransfusion hemoglobin levels and iron overload in thalassemia patients before and after treatment with nac for 3 months and with that of patients who served as controls.

Eligibility criteria:
inclusion criteria: * thalassemia major children on regular blood transfusion and iron chelation therapy exclusion criteria: * renal or hepatic impairments * complicated thalassemia major * non adherence to therapy or follow up visits * change in the iron chelation dose within 3 months before enrollment or during study period
effectiveness of pea compared to placebo on acute menstrual pain

Conditions: Menstrual Pain

Summary: this is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed palmitoylethanolamide (pea) compared to placebo on menstrual pain in otherwise healthy participants 18 years and over.


Eligibility criteria:
inclusion criteria: * women who experience mild to moderate menstruating pain * aged 18 years or over * history of over the counter (otc) analgesic use for the treatment of menstrual pain * self-reported history of menstrual cramp pain occurring during four of the past six menstrual cycles. * typically requires at least one dose of an otc analgesic medication such as naproxen, aspirin, ibuprofen or acetaminophen taken on at least 1 day of menstrual cycle for the treatment of mild to moderate menstrual cramp, and normally experiences pain relief from these medications. * otherwise healthy * able to provide informed consent * regular menstrual cycle (28 days ± 7 days) and period * agree not to participate in any other clinical trial while enrolled in this trial exclusion criteria: * secondary cause for dysmenorrhea (i.e. endometriosis, adenomyosis, uterine fibroids or infection) * any bleeding disorders, recent surgery or concurrent blood thinning treatment * unstable or serious illness (e.g., kidney, liver, git, heart conditions, diabetes, thyroid gland function, lung conditions, chronic asthma, diagnosed psychological or mood disorder) (1) * current malignancy (excluding bcc) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years * currently taking coumadin (warfarin), heparin, dalteparin, enoxaparin or other anticoagulation therapy * pregnant or lactating women * active smokers, nicotine use or drug (prescription or illegal substances) abuse * chronic past and/or current alcohol use (\>14 alcoholic drinks week) * allergic or hypersensitive to any of the ingredients in active or placebo formula * any condition which in the opinion of the investigator makes the participant unsuitable for inclusion * participated in any other clinical trial during the past 1 month 1. an unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. a serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
berberine treat metabolic syndrome in schizophrenia

Conditions: Metabolic Syndrome; Female; Schizophrenia

Summary: in early clinical study investigators confirmed that berberine could prevent glucose and lipid metabolism disorder in schizophrenia, so investigators intend to verify the effect and safety of berberine in treatment for metabolic syndrome in schizophrenia.

this study is an open lable clinical intervention trial, include 30 female subjects with diagnosis of schizophrenia and metabolic syndrome.participants will be given berberine（ 300mgtid） as an add-on therapy lasting 8 weeks.

Eligibility criteria:
inclusion criteria: 1. subjects with the diagnosis of schizophrenia depend on statistical manual, fifth edition (dsm-5) ; 2. female subjects aged 18-60 years; 3. monotherapy of atypical antipsychotics for 2 weeks or more , including olanzapine, clozapine, risperidone, and perphenazine； 4. subjects with diagnosis of metabolic syndrome depending on guidelines for the prevention and treatment of dyslipidemia in chinese adults in 2007; 5. the subjects and their guardians sign the informed consent agreement. exclusion criteria: 1. subjects with diagnosis of other psychiatric disorders except schizophrenia depend on dsm-5; 2. chronic organic diseases involving any central nervous system, such as tumors and inflammation, brain trauma, active seizures, vascular diseases, parkinson's disease, myasthenia gravis, and other degenerative diseases; 3. a history of gastrointestinal surgery or the presence of any possibility of interfering with the absorption, distribution, metabolism, or excretion of drugs situation; 4. used long-acting antipsychotic drugs or receive electroconvulsive therapy (mect) or receive transcranial magnetic stimulation therapy in the last 1 months; 5. serious physical diseases, including uncontrolled hypertension, severe cardiovascular, cerebrovascular, and pulmonary diseases, thyroid diseases, etc; 6. currently receiving anti-inflammatory or immunosuppressive treatment, including oral steroids; 7. a history of chronic infection, including tuberculosis, aids and hepatitis; 8. allergic to berberine,or hemolytic anemia or glucose -6- phosphate dehydrogenase deficiency; 9. pregnant women, lactating women； 10. participants were involved in other clinical trials within 1 months prior to the signing of informed consent 11. other reasons judged by the researchers to be inappropriate for the clinical study.

Keywords: metabolic syndrome schizophrenia efficacy female berberine
efficacy, tolerance and satisfaction with clobex® spray when used as monotherapy or add-on therapy in plaque psoriasis

Conditions: Psoriasis

Summary: evaluation of the effectiveness of clobex® spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

evaluation of the effectiveness of clobex® spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in the target plaque severity (tps) rating between weeks 0 and 4.

Eligibility criteria:
inclusion criteria: * moderate to severe plaque psoriasis between 3% and 20% of body surface area (bsa) with a target plaque severity (tps) of moderate to severe * at least 1 target site (not on the palms or soles of the feet) with a tps rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having well-circumscribed margins, and at least 1 cm in diameter * history of stable plaque psoriasis of greater than or equal to 3 months exclusion criteria: * diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis * psoriatic arthritis that was not stable or might have required a change in medication during the 4-week study period * plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits
effects of duloxetine on postoperative wound complication of total knee arthroplasty (tka) in central sensitization patients

Conditions: Osteoarthritis, Knee

Summary: postoperative wound complications such as wound dehiscence, skin necrosis, persistent wound drainage, delayed healing, and superficial skin infection could have devastating consequences, leading to arthroplasty failure and patient morbidity requiring additional operations and prolonging hospitalization with substantial burden in cost of care. recently, interest and research on central sensitization (cs) have been increasing. cs is closely correlated with excessive pain. it has two main characteristics: allodynia and hyperalgesia. cs is an abnormal and intense enhancement of pain mechanism by the central nervous system. one of the mechanisms by which this excessive pain occurs in cs is reduced activation of descending inhibitory pathway associated with deficiency in pathways primarily in response to serotonin and norepinephrine. serotonin plays an important role in normal wound healing by affecting the formation of neovascularization, inflammatory reactions, fibroblasts and tissue proliferation essential for wound healing. norepinephrine is also closely related to wound healing by controlling chemotaxis of macrophage essential for normal wound healing. cs is a risk factor for the development of postoperative wound complication after primary total knee arthroplasty (tka). preclinical models of central sensitization suggest that duloxetine is effective in the treatment. investigators will compare the wound complication following tka of central sensitization patients in duloxetine group (n=40) with those in non-duloxetine group (n=40). investigators will classify the central sensitization patients by central sensitization inventory and divide the central sensitization patients in to 2 groups (duloxetine and non-duloxetine group) randomly. investigators checks the wound complication after primary tka and visual assessment scale at preoperative, postoperative 2 days and 1, 2,6,12 weeks. all participants will receive postoperative pain control after tka using the same pain control regimen and wound dressing regimen except duloxetine.


Eligibility criteria:
inclusion criteria: * patients for total knee arthroplasty * having medicare insurance * central sensitization inventory (csi)\> 40 (central sensitization patient ) exclusion criteria: * rheumatoid arthritis * other inflammatory arthritis * neuropsychiatric patients * allergy or intolerance to study medications * patients with an american society of anesthesiologist (asa) classification of iv (angina, congestive heart failure, dementia, cerebrovascular accident) * chronic gabapentin or pregabalin use (regular use for longer than 3 months) * chronic opioid use (taking opioids for longer than 3 months) * alcohol, drug abuser * narcotics addiction

Keywords: duloxetine
exercise in asymptomatic pre-alzheimer's disease pilot study

Conditions: Alzheimer's Disease Prevention

Summary: researchers are trying to determine if cognitively normal subjects undergoing a moderate aerobic exercise program will accumulate less amyloid-ß (aβ) concentration in their brain than subjects undergoing a non-aerobic exercise program, and further evaluating the safety and imaging characteristics of florbetapir f 18, the radioactive drug that will allow us to image changes in the brain amyloid-ß (aβ).

after screening assessments have been completed, subjects will be randomized into one of two groups: aerobic exercise group and non-aerobic exercise group. all subjects will be trained on the physical activity scale for the elderly (pase), using the body media armband, and exercise diary. subjects will also complete an online food questionnaire. subjects assigned to the aerobic exercise group will work with an exercise trainer who will provide individual training (six half hour sessions) until they are proficient at the use of the equipment and understand goals. subjects will return to brooks family ymca at their convenience, but at a minimum of four times per week. subjects will complete the exercise journal daily and the physical activity scale for the elderly (pase) questionnaire on a monthly basis. subjects assigned to the non-aerobic exercise group will attend supervised classes on toning and stretching at a minimum of four times per week. subjects will complete the exercise journal daily and the physical activity scale for the elderly (pase) questionnaire on a monthly basis.

Eligibility criteria:
* 65 years of age or older. * not diagnosed with memory problems. * do not exercise in which you sweat and/or raise your pulse rate more than 30 minutes two times per week. * able to walk ten blocks (about one mile). * willing to participate in weekly exercise classes at the brooks ymca for six months. * able to have an mri and ct/pet scan.
risk factors of primary fibromyalgia

Conditions: Fibromyalgia

Summary: fibromyalgia (fm) is a condition with a different non-specific symptoms which lead to a difficult diagnosis. study suggests that osteopathy can help in improving fm symptoms, nevertheless, it can be difficult to identify which patients may benefit. the knowledge of fm risk factor can be useful tool for osteopaths and other clinician to implement a targeted, fast and multidisciplinary treatment protocol for those kind of patient.


Eligibility criteria:
inclusion criteria: * female patients * patient from piedmont * age between 20 and 65 years old * inform consent * for case group primary or secondary fibromyalgia exclusion criteria: * systemic or rheumatic or neoplastic diseases * for control group the presence of primary or secondary fibromyalgia

Keywords: osteopathy
surepulse oximeter - a targeted oxygenation observation

Conditions: Healthy

Summary: this clinical investigation will investigate how accurate the surepulse vs and surepulse vs patch (vsp) are for measuring blood oxygen levels (oxygen saturation). if the results are accurate, the vsp will be ready to apply for regulatory approval, meaning it could then be available for use on newborn babies in the national health service (nhs).

healthy volunteers who express an interest in the study and meet the eligibility criteria will be invited to participate in the study. this study will investigate the accuracy and safety of the surepulse vs and surepulse vs patch (vsp) in measuring blood oxygen levels. this is done by measuring blood oxygen levels across a range of values in healthy adults. the measurements from the vs and vsp will be compared to the known correct value. the study follows the internationally agreed standard for pulse oximeter approval. agreeing participants will have their name, contact details, medical history, height, weight, date of birth, skin colour, emergency contact details and address recorded, as necessary to conduct the study. after completion of the eligibility and consent process, participants will be enrolled in the study. healthy volunteers will have their blood oxygen levels temporarily reduced in a controlled and stepwise manner. oxygen levels will not be low for the entire duration of the session. oxygen levels will be reduced to a specific target for a few minutes at a time. volunteers will have a small tube inserted into an artery (blood vessel) in their wrist; this will be used to take blood samples throughout the session. the blood samples will be taken, analysed and destroyed in the same room. the session should take approximately 1.5 - 2 hours in total. the output from the study will be compared to the primary and secondary outcomes to evaluate the performance and safety of the device. this study is required for the surepulse vsp to be regulatory approved, meaning it could then become available in the nhs.

Eligibility criteria:
inclusion criteria: * age 18 to 55 * willing and able to provide written informed consent * healthy adult subjects (asa 1) * non-smoker * willing and able to comply with study procedures and duration exclusion criteria: * smokers or individuals exposed to high levels of carbon monoxide * compromised circulation, injury, or physical malfunction of the sensor sites which would limit the ability to test sites needed for the study * female subjects that are actively trying to get pregnant or are pregnant (conﬁrmed by health assessment form). n.b. all female participants will be offered a pregnancy test * unwillingness or inability to remove coloured nail polish from test digits (relevant for reference pulse oximeter) or to have medical monitoring attached * known health conditions disclosed on health assessment form which mean that participant is not healthy * allergy to lidocaine * allergy to adhesives used in medical dressings or tapes

Keywords: hypoxia oxygen saturation pulse oximetry
relation between body mass index and endometrial thickness

Conditions: Postmenopausal Bleeding

Summary: postmenopausal bleeding (pmb) is defined as recurrent attacks of bleeding occurring in women after menopause one year at least after stoppage of cycles \[

premalignant lesions and malignant lesions most commonly complex hyperplasia with atypia and carcinoma of the endometrium are present in 1/3 of patients evaluated for postmenopausal bleed-ing, and so investigations for cases of postmeno-pausal bleeding are mandatory

Eligibility criteria:
inclusion criteria: * menopausal women (defined as minimum of 1 year of amenorrhea after the age of 45 years if only the amenorrhea is not related to pregnancy, medication or disease), exclusion criteria: * women with chronic diseases as diabetes mellitus, hypertension or hematological disorders, those received hormone replacement therapy, tamoxifen or anticoagulant therapy and women with adnexal massed detected by tvus or apparent causes of bleeding from cervix or vagina e.g. ulcer were excluded.
a locally injected bradykinin antagonist for treatment of osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to determine whether intra-articular (knee joint) administration of men16132 is effective reducing the pain from knee osteoarthritis.

men16132 is a non-peptide bradykinin b2-receptor antagonist showing analgesic and anti-inflammatory activity in nonclinical osteoarthritis models. this study is being conducted as a dose finding study to determine the safety and efficacy of men16132, given as three doses/four treatment regimens in comparison to placebo, as well the time to onset and duration of effect.

Eligibility criteria:
main inclusion criteria: * male or female patients ≥40 years old. * symptomatic primary knee osteoarthritis (acr criteria) since ≥6 months prior to screening, kellgren lawrence grade 2 or 3, and representing an indication for intra-articular drug injection. * \>50 mm vas pain score assigned to the index knee at womac va 3.1-a1 (pain while walking on a flat surface). * \>125 mm vas pain score assigned to the index knee at womac va 3.1 a subscore (total pain). * pain in the index knee on at least 50% of the days in the month preceding the screening. main exclusion criteria: * patients with kellgren \& lawrence grade i or iv (doubtful or severe) osteoarthritis of the knee. * knee condition representing an indication for surgery * patients with inflammatory or crystal arthropathies, acute fractures, severe loss of bone density, bone necrosis. * patients with isolated patella-femoral syndrome or chondromalacia. * patients with oa predominant in the lateral compartment or any significant valgus deformity. * patients with any other disease or condition interfering with the free use and evaluation of the index knee for the 3 month duration of the trial (e.g. cancer, congenital defects, spine osteoarthritis). * major injury or surgery to the index knee within the previous 12 months prior to screening. * severe hip osteoarthritis ipsilateral to index knee. * any pain \>30 mm vas that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee). * any pharmacological or non-pharmacological treatment started or changed during 4 weeks prior to randomisation or likely to be changed during the duration of the study * use of systemic or topical corticosteroids \>10 mg prednisolone equivalent per day during 30 days prior to randomisation. * use of any pain or oa medication (e.g. nsaids, cox-2 inhibitors, analgesics) during 1 or 2 weeks prior to randomisation. * any intra-articular or local periarticular punction, injection or surgery to the index knee during the 6 months prior to screening.

Keywords: injections, intra-articular